Answers are grounded in this paper and cite their sources.
TCD in the bone marrow of patients with breast cancer is a valuable prognostic tool associated with negligible morbidity. Prospective randomized studies should be performed to determine whether TCD might replace axillary lymph node dissection in a defined subgroup of patients with small tumors.
No takes yet. Share an insight, caveat, or question.
Diel et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: